Oncology

Latest News

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com

NOTCH1 Levels Impact Immune Response in SCLC

By Jared Kaltwasser

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe

Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

By Jared Kaltwasser

August 31st 2025

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com

Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

By Jared Kaltwasser

August 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 8th 2016

Family Caregivers of Cancer Patients Vulnerable to Depression, Anxiety

Surabhi Dangi-Garimella, PhD

Nearly 25% to 33% of family caregivers across the United States tend to ignore their own needs, resulting in poorer self-care and symptoms of depression and anxiety, according to a research study to be presented at the 2016 Palliative Care in Oncology Symposium.

September 8th 2016

Most US Adults Favor Prohibiting Tobacco Sales in Retail Pharmacies

More communities across the country have implemented policies prohibiting the sale of tobacco products in retail pharmacy stores in an effort to respond to pharmacists’ concerns about their professional obligation to promote health and wellness among patrons in their stores.

September 7th 2016

Panel Delivers Recommendations for the Cancer Moonshot

Surabhi Dangi-Garimella, PhD

A Blue Ribbon Panel of experts from diverse healthcare fields has provided preliminary recommendations to achieve the objectives of the government's Cancer Moonshot initiative.

September 7th 2016

Pembrolizumab's Breakthrough Toughens the Playing Field in NSCLC

Surabhi Dangi-Garimella, PhD

The FDA has accepted for priority review the supplemental Biologics License Application for Merck's pembrolizumab (Keytruda).

September 6th 2016

Whole-Brain Radiotherapy Unnecessary for Brain Metastases in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

Patients with non-small cell lung cancer whose disease has metastasized to the brain can do without whole-brain radiotherapy, according to a new study published in the journal Lancet.

This Week in Managed Care: September 3, 2016

September 3rd 2016

This Week in Managed Care: September 3, 2016

This week in managed care, the top stories included proposals from CMS to shore up the Affordable Care Act's marketplaces, research that highlighted the link between duration of obesity and cancer risk for women, and the results of an FDA diabetes workshop.

September 2nd 2016

Information Disparity a Major Concern of Breast Cancer Survivors

Surabhi Dangi-Garimella, PhD

Researchers at the Sidney Kimmel Cancer Center collated concerns of African American breast cancer survivors to find that medical mistrust was a commonly raised issue.

September 1st 2016

Study Highlights Inconsistent Cancer Screening Guidelines Among High-Risk Transplant Patients

Surabhi Dangi-Garimella, PhD

Results of a new study published in the American Journal of Transplantation has found that international guidelines lack standardization on screening recommendations for solid organ transplant recipients.

September 1st 2016

Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab

Surabhi Dangi-Garimella, PhD

Roche has announced that phase 3 results from the OAK study evaluating atezolizumab (Tecentriq) indicate improved overall survival compared with docetaxel in patients with locally advanced or metastatic non—small cell lung cancer.

August 31st 2016

COA-Commissioned Report Blames PBMs for Restricting Physician Dispensing

Surabhi Dangi-Garimella, PhD

A new report by the law firm Frier Levitt, commissioned by the Community Oncology Alliance, has found that restrictive tactics by pharmacy benefit managers, particularly in the specialty pharmacy arena, could restrict patient access to much needed medications.

August 31st 2016

Evidence-Based Oncology Looks at How the Cost of Cancer Care Affects Treatment

At what point does the cost of cancer therapy affect the results? The current issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, takes on one of today’s biggest treatment challenges: the eye-popping prices of today’s new therapies can erect barriers to care before it begins.

August 30th 2016

Translating a Radiologist's Visual Expertise Into Improving CAD

Surabhi Dangi-Garimella, PhD

Scientists at Brigham and Women’s Hospital are evaluating the depth of a trained radiologist’s eye to detect abnormalities on a mammogram, in an attempt to improve screening and earlier detection of disease.

August 30th 2016

Cancer Risk Increases the Longer a Woman Is Overweight or Obese

A study found that the longer a woman is overweight or obese, the higher the risk of developing several forms of cancer, plus the degree of being overweight plays a role in the risk of developing cancer.

August 29th 2016

PIONEER Trial: Hope for Patients With Unresectable Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

Researchers at Cancer Research UK have developed a strategy to make pancreatic cancer more responsive to chemotherapy and radiation.

August 29th 2016

Infographic: How Young Adult Cancer Survivors Are Hit Hard by Treatment Costs

Laura Joszt, MA

In the August issue of Evidence-Based Oncology, The Samfund's Samantha Watson, MBA, and Michelle Landwehr, MPH, outline how young adult cancer survivors are disproportionately affected by treatment costs. This infographic breaks down the vicious cycle these patients get stuck in.

August 29th 2016

A Thaw in the US—Cuba Relation Could Yield a Lung Cancer Vaccine

Surabhi Dangi-Garimella, PhD

A vaccine, under development in Cuba for more than 2 decades, has shown potential to improve survival in patients with advanced non-small cell lung cancer.

August 26th 2016

Report in NEJM Links 8 More Cancers With Obesity

Researchers found a dose-response relationship for several cancers involved in eating, meaning the higher the weight, the greater risk of cancer.

August 26th 2016

5 Ongoing Initiatives at the FDA

Surabhi Dangi-Garimella, PhD

The FDA has several projects under its wings that can improve the regulatory aspect of drug development and healthcare overall.

August 25th 2016

Does Precision Medicine Aid or Complicate Treatment Decisions in Cancer?

Surabhi Dangi-Garimella, PhD

Based on the results of the MINDACT trial, investigators have concluded that chemotherapy is unnecessary in women with early-stage breast cancer who have a high clinical and low genomic risk of disease recurrence.

August 25th 2016

Dynamic Nature of Breast Cancer Resistance: The HER2 Switch

Surabhi Dangi-Garimella, PhD

Research at Massachusetts General Hospital has provided vital leads that can explain drug resistance observed in breast cancer.

August 24th 2016

Overdiagnosis Blamed for Global Increase in Thyroid Cancer

Surabhi Dangi-Garimella, PhD

Researchers from Italy and France have coauthored an article in the New England Journal of Medicine that blames novel diagnostic technologies, increased access to healthcare services, and increased medical surveillance for the thyroid cancer epidemic around the world

August 23rd 2016

The Final Word Is Out: Menopausal HRT Triples the Risk of Breast Cancer

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Institute of Cancer Research has substantiated that hormone replacement using estrogen and progesterone increases the risk of breast cancer, especially with longer use.

August 22nd 2016

Researchers Propose a Bundled Payment Model for Breast Screening

Surabhi Dangi-Garimella, PhD

A new report by the Harvey L. Neiman Health Policy Institute recommends a bundled payment model for breast cancer screening, with the objective of improved patient care and a more efficient use of healthcare resources.

August 22nd 2016

Adverse Sociodemographic Conditions Reduce Survival in Younger Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Factors such as insurance status and being married are significant determinants of survival compared with race/ethnicity, in patients with multiple myeloma who are less than 65 years of age.

This Week in Managed Care: August 20, 2016

August 20th 2016

This Week in Managed Care: August 20, 2016

This week, the top stories in managed care included Aetna's announcement that it was pulling back its participation on the Affordable Care Act exchanges, the annual meeting of the American Association of Diabetes Educators outlined how existing sites can help roll out the Diabetes Prevention Program nationwide, and hospital leaders gave their opinions on CMS' hospital readmission program.

August 19th 2016

The Toll of Cancer Care - Clinical and Financial Toxicity

Joseph Alvarnas, MD

This issue of Evidence-Based Oncology is dedicated to understanding the implications, scope, and opportunities within the realm of cost sharing in oncology.

August 19th 2016

Does the Cost-Sharing Burden Influence Cancer Outcomes?

Surabhi Dangi-Garimella, PhD

Financial burden is a potential nonclinical adverse event in cancer patients. As patients, especially those in the lower income ranges and the middle class, struggle to meet their medical bills, the likelihood of them skipping doses or doctor’s visits is quite high.

August 19th 2016

Young Adult Cancer Survivors Disproportionately Affected by Treatment Costs

Samantha Watson, MBA Michelle Landwehr, MPH

Young adult (YA) cancer survivors are hit the hardest in the wallet by their treatment. The average net worth of YAs who have received grants from The Samfund is a staggering —$35,000, while their counterparts in the general population is $68,000

August 19th 2016

Precision Oncology: Why Payers Should Initiate CGP Coverage Now!

Jerry Conway Ingrid Marino, MS, CGC

Precision oncology, or the clinically and financially efficient use of genomically matched treatments and clinical trials, is evolving as a potentially important starting point for cancer care within successful alternative payment models.

August 19th 2016

Proton Therapy Eliminates Unnecessary Radiation Exposure and Is Medically Necessary

Steven J. Frank, MD

When it comes to health coverage, most Americans face an unnerving reality-they have no idea what is covered under their health insurance policy until after they are affected by illness or disease.

...

95 96 97 98 99 100 101 102 103

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions